Total amount: € 0,00
Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,014
Online ISSN 1827-1820
ADVANCES IN PSORIASIS
Martin-Ezquerra G., Ferran M., Pujol R. M.
Department of Dermatology Hospital del Mar-IMAS Barcelona, Spain
Psoriasis is a clinically heterogeneous disease with a wide range of topical and/or systemic therapeutic options. Topical treatments are often prescribed either as the main treatment for mild forms of the disease, or in combination with systemic treatments in more severe forms. Classic phototherapy modalities, including Psoralen plus UVA (PUVA) and narrow band UVB therapy are still essential tools in the management of moderate-severe psoriasis. Some new phototherapy system devices have recently been developed for localized and/or resistant individualized lesions. Classic systemic treatments for psoriasis include methotrexate, cyclosporine and acitretin. They are usually prescribed in patients with severe forms of the disease and a systematized control of potentially side effects is needed. The development of a new group of biological drugs (anti-TNF and specific monoclonal antibodies) has represented a true revolution in the management of the severe forms of the disease. Biological drugs are usually prescribed in unresponsive cases to conventional treatments, allowing a better management of the so-called “high-need patients”. Specific guidelines to facilitate monitoring have been proposed. However, considering the variability of both the therapeutic response and compliance to topical and systemic treatments, individualized treatments are often necessary. In this article “the state of the art” of the different available therapeutic options for psoriasis is updated and reviewed.